Corrections to “Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis”

Ann Oncol 2012; 23: 1130–1137 (doi: 10.1093/annonc/mdr432) In the original article, the disclosure was incomplete. This has now been updated to add the statement for J. Baselga: JB is the consultant and on the advisory board for Roche and Novartis. Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysisAnnals of OncologyVol. 23Issue 5PreviewBevacizumab is a monoclonal antibody against vascular...